Ranibizumab Does Not Worsen Retinal Degeneration in Intermediate AMD, Study Finds
A post hoc analysis of the PREVENT trial suggests quarterly ranibizumab did not appear to affect drusen volume, drusen area, or GA progression compared to sham.
United States Clementk Chan Desert Retina Consultants Southern California Desert Retina Unifeye Vision Age Related Eye Disease Study
Source: hcplive.com